Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders.
Trevena’s novel pipeline includes product candidates aimed at moderate-to-severe acute pain, migraine, opioid use disorder, and other CNS indications, as well as acute lung injury / acute respiratory distress syndrome (COVID-19). All of the company’s assets have unique mechanisms of action (MOA) that are designed to optimize receptor pharmacology. The result is a pipeline of innovative therapies targeting well-known receptors, but with a potentially more favorable pharmacological profile than current drugs targeting the same receptor class.
Trevena is guided by an innovative spirit and an unwavering commitment to patients. It is a place driven by its employees – passionate and talented industry experts who operate with integrity, transparency, and respect for one another. Trevena employees are united in one mission: to deliver new medicines that address critical areas of need in CNS disorders.